[The role of chemotherapy in metastatic pulmonary tumors in a disease-oriented phase II study of anticancer agent].
It is essential to conduct a precise and scientific phase II study of anticancer agent to ascertain active drugs for the establishment of standard chemotherapeutic regimens. In this review, we discuss the rationales of phase II study of agents against metastatic pulmonary tumors as well as of postsurgical adjuvant chemotherapy. The results of the phase II study of cisplatin against metastatic pulmonary tumors in the National Cancer Center Hospital are discussed from the standpoint of a drug- and disease-oriented phase II study.
D000880:Anthraquinones / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000473:pathology; D004341:Drug Evaluation / Q000379:methods; D006258:Head and Neck Neoplasms / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008942:Mitoxantrone
D000880:Anthraquinones; D000970:Antineoplastic Agents; D008942:Mitoxantrone; D002945:Cisplatin